Scholarlink

<p>This study focuses on designing curcumin-loaded polycaprolactone (M-PCL) nanocarriers conjugated with Lactoferrin (Lf) to enhance glioblastoma treatment. The synthesized nanocarriers were analyzed using various characterization techniques such as FT-IR, UV, TGA, and DLS. Cytotoxicity of the developed nanocarriers was assessed via the MTT assay over 24&#xa0;h against U-87MG and HBME cell lines. For the U-87MG cells, Lf-conjugated nanoparticles (NPs) (M-PCL-Cur-Lf) demonstrated a significantly lower IC<sub>50</sub> value of 127.58&#xa0;μg/mL compared to non-conjugated nanoparticles, which had an IC<sub>50</sub> of 148.41&#xa0;μg/mL. Similarly, Lf-conjugated nanocarriers exhibited an IC<sub>50</sub> value of 127.58&#xa0;μg/mL against HBME cells, outperforming their non-conjugated counterparts. Morphological analysis using microscopy revealed that the cells treated with M-PCL-Cur-Lf displayed distinct structural alterations, such as shrinkage and membrane blebbing. Cellular uptake studies on U-87MG cells measured changes in green fluorescence intensity via fluorescence microscopy, indicating enhanced drug uptake due to receptor interactions. These results suggest that M-PCL-Cur-Lf nanocomposites hold promise as a potential therapeutic option for glioma treatment.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Design and Evaluation of Lactoferrin-Conjugated Cur-M-PCL Nanocarriers for Targeted Glioblastoma Multiforme Therapy

  • 期刊论文

  • 发表日期：

    2025年8月29日

查看全文
  • Sandhya Ramesh,
  • Geetha B. Heggannavar,
  • Mahadevappa Y. Kariduraganavar,
  • Amar K. Durgannavar

摘要

This study focuses on designing curcumin-loaded polycaprolactone (M-PCL) nanocarriers conjugated with Lactoferrin (Lf) to enhance glioblastoma treatment. The synthesized nanocarriers were analyzed using various characterization techniques such as FT-IR, UV, TGA, and DLS. Cytotoxicity of the developed nanocarriers was assessed via the MTT assay over 24 h against U-87MG and HBME cell lines. For the U-87MG cells, Lf-conjugated nanoparticles (NPs) (M-PCL-Cur-Lf) demonstrated a significantly lower IC50 value of 127.58 μg/mL compared to non-conjugated nanoparticles, which had an IC50 of 148.41 μg/mL. Similarly, Lf-conjugated nanocarriers exhibited an IC50 value of 127.58 μg/mL against HBME cells, outperforming their non-conjugated counterparts. Morphological analysis using microscopy revealed that the cells treated with M-PCL-Cur-Lf displayed distinct structural alterations, such as shrinkage and membrane blebbing. Cellular uptake studies on U-87MG cells measured changes in green fluorescence intensity via fluorescence microscopy, indicating enhanced drug uptake due to receptor interactions. These results suggest that M-PCL-Cur-Lf nanocomposites hold promise as a potential therapeutic option for glioma treatment.

Graphical Abstract